At the recently concluded "Annual Grand Event" in the field of urology—the 32nd Annual Meeting of the Urological Association of the Chinese Medical Association (CUA2025)—Professor Yang Xuecheng, Director of the Department of Urology at Qingdao University Affiliated Hospital, delivered a special presentation on the near-infrared targeted fluorescent contrast agent independently developed by SIGNDO Biotechnology. The new achievement he showcased, Injection DGPR1008, with its core advantages of "lighting up tumors for precise surgery," provides a breakthrough solution for the treatment of prostate cancer, sparking enthusiastic discussions among all participating experts and scholars.
Clinical
Pain Points Urgently Need Breakthroughs, and Innovative Technologies Emerge as
the Times Require
As
a "health killer" in the male genitourinary system, the diagnosis and
treatment of prostate cancer have long faced critical challenges. According to
the latest data from the National Cancer Center of China, the incidence rate of
prostate cancer in China has increased at an average annual rate of 7.1%, and
by 2022, the incidence rate had risen to 18.61 per 100,000 people. More
critically, in traditional surgery, blurred tumor boundaries and difficulty in
identifying small lesions lead to a positive surgical margin rate as high as
25%-30%—a core reason for the persistently high recurrence rate (40%-50%) among
patients.
"How to 'see clearly' tumors during surgery is the key to improving surgical precision," emphasized Director Yang Xuecheng in his report. With over 20 years of clinical experience in urology, he has specialized in the minimally invasive treatment of genitourinary system tumors and has led the completion of more than 2,000 laparoscopic and robot-assisted radical prostatectomies. It was based on his profound insight into clinical pain points that he initiated industry-academia-research collaboration with SIGNDO Biotechnology to jointly promote the clinical translation of the DGPR1008 contrast agent.
Targeted
Imaging Breaks New Ground and Empowers Precise Clinical Surgery
In his report, Director Yang Xuecheng intuitively demonstrated the "strong capabilities" of the DGPR1008 contrast agent through clinical cases: after intravenous injection of the contrast agent before surgery, the tumor area was clearly displayed as a "fluorescent highlight area" during surgery via the near-infrared imaging system, and the tumor-to-background ratio (TBR) far exceeded that of similar foreign products. Moreover, DGPR1008 accurately identified small metastatic lymph nodes, providing "real-time navigation" for surgeons to completely resect lesions.
The
advantages of this innovative product can be summarized in four points:
☆Real-time cellular-level imaging: Distinguishes malignant tumors from normal tissues in real time during surgery
☆Ultra-clear boundary visualization: Precisely shows the tumor invasion range to ensure complete resection
☆Key protection function: Maximizes the preservation of sexual function and urinary control nerves
☆Small lesion clearance: Identifies small lesions that are difficult to detect with traditional imaging techniques
Empowering
a Promising Clinical Future and Driving the Upgrade of Urological Diagnosis and
Treatment
This
special presentation at the CUA Annual Meeting not only represents
authoritative recognition of the clinical value of the DGPR1008 contrast agent
but also marks that China’s domestic near-infrared targeted imaging technology
has officially entered the international advanced ranks. Director Yang Xuecheng
stated: "In the future, we will continue to collaborate with Xindou
Biotechnology to expand the sample size of clinical trials, promote the
product’s early market approval, and enable more patients in primary hospitals
to benefit from precision medicine."
With
the further research, development, and promotion of the DGPR1008 contrast
agent, it is expected that urological oncology surgery in China will achieve a
leap from "experience-based" to "precision-based,"
injecting strong momentum into improving the national level of urological
health.
【Scan and follow us】
